Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy

Journal of Immunology

Volumn 165, Issue 8, 2000, Pages 4246-4253

  Hu, H M ^a   Winter, H ^a   Urba, W J ^a   Fox, B A ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HELPER CELL; IMMUNOLOGICAL MEMORY; KNOCKOUT GENE; LUNG METASTASIS; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR MODEL; TUMOR RESISTANCE; VACCINATION;

EID: 0034668011     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.8.4246     Document Type: Article

References (49)

1. Cross-presentation: A general mechanism for CTL immunity and tolerance
2. + T cell responses in antitumor immunity
3. + T cells in the antitumor immune response
4. + T cell help
5. CD4 T cells and their role in antitumor immune responses
6. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
7. Cancer vaccines
8. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells
9. + T cell response depending on the route of immunization
10. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
11. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo
12. Adoptive immunotherapy of a newly induced sarcoma: Immunologic characteristics of effector cells
13. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
14. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
15. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells
16. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
17. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
18. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
19. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes
20. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma
21. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
22. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor
23. + T cells against the wild-type tumor: Correlation with antigen presentation capability
24. In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes
25. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
26. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
27. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
28. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter
29. Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis
30. + T cells
31. + T-helper and a T-killer cell
32. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
33. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
34. Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins
35. + T cells in major histocompatibility complex class II-deficient mice
36. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells
37. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO/CD95L)
38. Long-lasting CD8 T cell memory in the absence of CD4 T cells or B cells
39. Viral immune evasion due to persistence of activated T cells without effector function
40. + T cell numbers are maintained during γ-herpesvirus reactivation in CD4-deficient mice
41. + T cells but confers minimal survival advantage on CD4-deficient mice
42. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein
43. A melanosomal membrane protein is a cell surface target for melanoma therapy
44. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity
45. Tumor immunity and autoimmunity induced by immunization with homologous DNA
46. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
47. Coupling and uncoupling of tumor immunity and autoimmunity
48. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
49. Heteroclitic immunization induces tumor immunity